Athira Pharma presented preclinical data on ATH-1105's neuroprotective effects in ALS at an international symposium in Montreal.Quiver AI SummaryAthira Pharma, Inc., a clinical-stage biopharmaceutical...
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.
Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of...
Fosgo-AM, the active metabolite of Fosgonimeton (ATH-1017), demonstrates neuroprotective effects in primary neuron culturesNew orally available small...
BOTHELL, Wash., July 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...
Its mid-stage clinical trial failed to help patients with Alzheimer's.
Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and...